Zika virus-like particle production in a stirred tank bioreactor using a baculovirus/insect cell system
- PMID: 40982077
- DOI: 10.1007/s00449-025-03233-2
Zika virus-like particle production in a stirred tank bioreactor using a baculovirus/insect cell system
Abstract
Zika virus (ZIKV) was declared a public health emergency in 2016, yet effective vaccines are still needed. Among the immunization platforms under evaluation, virus-like particles (VLP) are promising candidates. Growth, metabolism, and respiration are among the cell host processes that are essential for optimizing and characterizing VLP upstream production stage. These cell functions can be influenced by factors such as culture medium composition and the multiplicity of infection (MOI) in viral vector-based expression systems. This study investigated the effects of three MOIs (2, 6, and 10) in a baculovirus/Sf9 insect cell system on ZIKV VLP production with and without medium supplemented with 0.028 mM cholesterol and 6 nM albumin. Medium supplementation during the growth phase increased the cell growth rate from 0.357 × 104 to 0.565 × 104 . In addition, cholesterol and albumin supplementation increased the expression of ZIKV structural proteins during infection. Higher MOIs led to increased substrate uptake and metabolite production, suggesting intensified cellular metabolism. Western blot analysis revealed that under nonsupplemented conditions, the highest MOI resulted in increased ZIKV envelope production, with a maximum protein concentration range of 1.049 higher when comparing 6 to 2 MOI via SDS‒PAGE densitometry. However, a lower MOI, 2 , might be advantageous when a supplemented medium is used, which upper limit for ZIKV envelope protein concentration was 1.834 higher than that from the nonsupplemented assay in semiquantitative analysis, which reached 23.504 of ZIKV envelope protein. The resulting VLP had an average diameter of ~ 60 nm, making them suitable for vaccine applications.
Keywords: Baculovirus/insect cell system; Biochemical engineering; Medium supplementation; Multiplicity of infection; Virus-like particles; Zika virus.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that they have no conflicts of interest.
References
-
- International Committee on Taxonomy of Viruses (2025) Family: Flaviviridae Genus: Orthoflavivirus. https://ictv.global/report/chapter/flaviviridae/flaviviridae/orthoflavivirus . Accessed 4 May 2025
-
- Lin H-H, Yip B-S, Huang L-M, Wu S-C (2018) Zika virus structural biology and progress in vaccine development. Biotechnol Adv 36:47–53. https://doi.org/10.1016/j.biotechadv.2017.09.004 - DOI - PubMed
-
- Pielnaa P, Al-Saadawe M, Saro A et al (2020) Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. Virology 543:34–42. https://doi.org/10.1016/j.virol.2020.01.015 - DOI - PubMed
-
- World Health Organization (WHO) (2022) Zika virus. https://www.who.int/news-room/fact-sheets/detail/zika-virus . Accessed 27 May 2024
-
- World Health Organization (WHO) (2024) Vector-borne diseases. https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases . Accessed 3 Jul 2025
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
